1.46
0.68%
-0.01
After Hours:
1.48
0.02
+1.37%
SELLAS Life Sciences Group Inc stock is currently priced at $1.46, with a 24-hour trading volume of 1.13M.
It has seen a -0.68% decreased in the last 24 hours and a +3.55% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.48 pivot point. If it approaches the $1.41 support level, significant changes may occur.
Previous Close:
$1.47
Open:
$1.48
24h Volume:
1.13M
Market Cap:
$84.32M
Revenue:
-
Net Income/Loss:
$-37.34M
P/E Ratio:
-0.9419
EPS:
-1.55
Net Cash Flow:
$-36.91M
1W Performance:
+7.75%
1M Performance:
+3.55%
6M Performance:
+47.92%
1Y Performance:
-13.61%
SELLAS Life Sciences Group Inc Stock (SLS) Company Profile
Name
SELLAS Life Sciences Group Inc
Sector
Industry
Phone
646 200 5278
Address
Times Square Tower, Suite 2503 7 Times Square, New York, NY
SELLAS Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
Nov-01-18 | Initiated | Oppenheimer | Outperform |
Apr-02-18 | Initiated | H.C. Wainwright | Buy |
Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
SELLAS Life Sciences Group Inc Stock (SLS) Latest News
SELLAS Life Sciences Group Inc (SLS) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
The InvestChronicle
A look into SELLAS Life Sciences Group Inc (SLS)'s deeper side – Sete News - SETE News
SETE News
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Up 23.3% in April - MarketBeat
MarketBeat
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
GlobeNewswire
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Yahoo Finance
SELLAS Life Sciences Group Inc (SLS) stock analysis: A comprehensive overview – US Post News - US Post News
US Post News
SELLAS Life Sciences Group Inc Stock (SLS) Financials Data
SELLAS Life Sciences Group Inc (SLS) Net Income 2024
SLS net income (TTM) was -$37.34 million for the quarter ending December 31, 2023, a +9.59% increase year-over-year.
SELLAS Life Sciences Group Inc (SLS) Cash Flow 2024
SLS recorded a free cash flow (TTM) of -$36.91 million for the quarter ending December 31, 2023, a -30.38% decrease year-over-year.
SELLAS Life Sciences Group Inc (SLS) Earnings per Share 2024
SLS earnings per share (TTM) was -$1.36 for the quarter ending December 31, 2023, a +39.01% growth year-over-year.
About SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Cap:
|
Volume (24h):